阿尔康CEO受访泛论美国药品定价联动机制，称部分药企或因此放弃在欧洲上市

Alcon Inc. Chief Executive Officer David Endicott warned that the Trump administration’s push to link US drug prices to those in other countries abroad could result in some medicines not being launched in Europe.

Many innovative products are cheaper in other countries and the White House wants US prices to align with those. Some companies may choose not to sell in Europe rather than cut their prices in the huge American market.

The idea is that “different prices outside the US are going to be negotiated by the US,” Endicott said in an interview with Bloomberg Television Monday. “We’re trying to make sure we maintain access as broadly as we can, but obviously being responsible to shareholders.”

Alcon, a Swiss eye-care company that makes surgical equipment, contact lenses and medicines, was among nine additional pharmaceutical and biotech companies that reached drug-pricing agreements with the US at the end of August.

The agreement is aimed at ensuring Alcon’s medicines remain available to US patients as the administration seeks to tie US prices to those charged in other developed countries.

“Every market is going to develop its own reimbursement system, its own negotiation, and we do that around the world,” Endicott said. “We’ll continue to push around the world to figure out what that implication means as we negotiate prices as we always have.”